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 1 
Introduction 
 In many ways, the United States is the Pharmaceutical Capital of the World.  Four 
out of the top 10 grossing pharmaceutical companies are based in the United States and 
the US develops more drugs than any other nation1.  Americans also consume more drugs 
than almost any other developed nation, at an average of 2.2 prescriptions taken regularly 
per capita2.  However, the US also spends more on prescription drugs than any other 
nation3.  The US spends twice the average amount paid by industrialized nations for 
pharmaceuticals per capita calculated by the Organization for Economic Co-operation 
and Development4.   While we have no centralized, single-payer system, our public 
expenditure on healthcare overall is comparable with that of most European governments 
with single-payer systems (see Appendix 3)5. What distinguishes us from these other 
industrialized countries is our massive private expenditure (a combination of premiums, 
deductibles, co-pays, and out of pocket costs) on healthcare and prescription drugs, which 
exceeds our public expenditure and is more than double the next largest private 
contribution6,7.  Furthermore, our drug spending has been steeply and steadily rising in 
                                                        
1 Jurney, Corinne. "2016 Global 2000: The World's Largest Drug And Biotech Companies." 
Forbes. July 28, 2016. Accessed March 01, 2017. 
https://www.forbes.com/sites/corinnejurney/2016/05/27/2016-global-2000-the-worlds-largest-drug-and-
biotech-companies/#25e7fcc2cf19.  
2 Squires, David, and Chloe Anderson. "U.S. Health Care from a Global Perspective: Spending, 
Use of Services, Prices, and Health in 13 Countries." The Commonwealth Fund. October 08, 2015. 
Accessed January 20, 2017. http://www.commonwealthfund.org/publications/issue-briefs/2015/oct/us-
health-care-from-a-global-perspective.   
3 OECD (2015), “Pharmaceutical spending trends and future challenges”, in Health at a Glance 
2015: OECD Indicators, OECD Publishing, Paris. 30.  
DOI: http://dx.doi.org/10.1787/health_glance-2015-5-en  
4 Ibid, 31.  
5 Kane, Jason. "Health Costs: How the U.S. Compares With Other Countries." PBS. March 24, 
2017. Accessed April 02, 2017. http://www.pbs.org/newshour/rundown/health-costs-how-the-us-compares-
with-other-countries/.  
6 Ibid 
7 OECD (2015), “Pharmaceutical spending trends and future challenges”, 34.  
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the last 10 years and is projected to continue rising at higher and higher rates (Appendix 
2)8.  
 America’s high pharmaceutical spending is part of a trend in high healthcare costs 
in the United States.  The US spends 16.9% of its GDP on health costs, while the OECD 
average is 9.3% of GDP.9  Our public expenditure amounts to half of our overall 
healthcare costs while the average OECD nation has a 72% public expenditure10.  
Similarly, roughly two thirds of our pharmaceutical spending comes from private 
insurance and out of pocket spending.11   While the US Government (and thus the 
American tax-payer) is paying roughly the same amount per capita as other OECD 
nations, American consumers are being asked to pay again through private insurance and 
out-of-pocket costs and thus are effectively double charged12,13.  What is remarkable 
about American healthcare is that, while we pay twice the average of comparable 
countries our health outcomes are average at best and by some measures significantly 
worse.  In 2012, the United States had an average life-expectancy at birth of 78.7 years 
compared to the OECD average of 80.2 years, this earned us a ranking of 27th out 34 
OECD nations14.  Our mortality rate for cardio-vascular disease was 261.2 deaths per 
100,000 compared to the average 296.4 deaths per 100,000 landing us a rank of 17/3415.  
Mortality from cancer in the US was 198.7 out of 100,000 compared to 213.1, which 
                                                        
8 "10 Essential Facts About Medicare and Prescription Drug Spending." The Henry J. Kaiser 
Family Foundation. July 07, 2016. Accessed January 20, 2017. http://kff.org/infographic/10-essential-facts-
about-medicare-and-prescription-drug-spending/.   
9 Kane, Jason. "Health Costs: How the U.S. Compares With Other Countries." (2017) 
10 Ibid.  
11 OECD (2015), “Pharmaceutical spending trends and future challenges”, 34. 
12 Ibid.  
13 Kane, Jason. "Health Costs: How the U.S. Compares With Other Countries." (2017) 
14 "OECD Health Statistics 2014-How does the United States Compare?" Organization for 
Economic Cooperation and Development-Health Data. 2015. Accessed April 30, 2017. 
www.oecd.org/health/healthdata.  
15 Ibid.  
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placed us at 25/3416.  These statistics place us squarely in the middle of the pack, which 
might be respectable if we were not paying more than any other comparable country for 
our care.  And those are our good stats, our obesity rates land us a number one ranking, 
meaning we are the most obese of all industrialized nations17.  These statistics show that 
while we pay more than any other nation, we are not healthier than other nations.  So 
what are paying for if not health outcomes? 
While prescription drugs are not the only expensive aspect of our health system, it 
is an aspect that touches the lives of most Americans, it accounts for a large percentage of 
our health expenditure, and the costs are prohibitive for many people.  54% of Americans 
take at least one prescription drug regularly and many take several drugs regularly18.  
Around a quarter of all Americans taking prescription drugs (14% of all Americans) 
admit to difficulty affording their medication19.  Among uninsured Amerians, 17% stated 
that at some point they had forgone, delayed or decreased a prescription dose because of 
the cost of their medication20.  Even among the insured, 5% report engaging in the same 
tactics because of the high prices, this amounts to 1/10 Americans being unable to afford 
their prescribed drugs21.  Most Americans (72%)—whether or not they are taking drugs 
themselves—believe that the costs of pharmaceuticals are too high22.   
                                                        
16 Ibid. 
17 Ibid.  
18 Brodie, Mollyann, Jamie Firth, and Bianca DiJulio. "Kaiser Health Tracking Poll: August 
2015." The Henry J. Kaiser Family Foundation. August 20, 2015. Accessed January 10, 2017. 
http://kff.org/health-costs/poll-finding/kaiser-health-tracking-poll-august-2015/. 
19 Ibid.  
20 "How does cost affect access to care?" Peterson-Kaiser Health System Tracker. November 29, 
2016. Accessed January 25, 2017. http://www.healthsystemtracker.org/chart-collection/how-does-cost-
affect-access-to-care/.  
21 Ibid. 
22 Brodie, et.al. "Kaiser Health Tracking Poll: August 2015." 
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 It is clear that both compared to other countries and compared to what our own 
citizens can afford, the US is facing high costs for pharmaceuticals.  The purpose of this 
exploration is to determine (1) whether these high costs are ethically justifiable and (2) 
who is responsible for making drugs more affrodable. In considering these questions, we 
will need to start with a framework for how we consider our pharmaceutical system.  In 
order to limit the scope of this study and to make any policy recommendations plausible, 
we will start with a non-ideal model.  There will be no attempt in this paper to 
fundamentally restructure the US healthcare or pharmaceutical systems, and all policy 
recommendations will maintain the multi-payer healthcare system and the 
private/corporate drug industry. Rather, I will look at the industry as it is, consider how 
the many facets of our healthcare industry and regulations influence prices and 
consumers, and make recommendations to increase or decrease regulations as necessary 
to make drugs more affordable.   These policy options also will exist within the real 
world, and will consist of public and private efforts that could be made at any moment 
that the political will should arise.  
 Since we will be working within the system that already exists, in order to 
determine whether prices are justified we must consider what the goals of our system are. 
These goals can be summarized by the values of fairness, equity and quality; and in order 
for the high prices paid to be ethically justified, the costs must contribute to the 
achievement of these goals.  The goal of any healthcare system is to maximize population 
health by providing accessible, affordable and good quality care that maintains individual 
liberty and autonomy in health decisions23.  A further goal that should guide all health 
                                                        
23 Faden, Ruth and Shebaya, Sirine. "Public Health Ethics." In The Stanford Encyclopedia of 
Philosophy, edited by Edward N. Zalta. Summer 2010 ed., 2010. 
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systems is to limit social injustice and maximize social good, while correcting for poverty 
and systematic disadvantage24.  In America our private pharmaceutical sytems mean that 
profits are necessarily a goal.  While this is not directly an ethical goal, prices cannot be 
justified if they would  make pharmaceutical companies unprofitable, because it would 
make the achievement of our ethical goals impossible.  Problems in setting ethical prices 
arrise when there is conflict between our ethical goals or between the ethical goals and 
the necessity of profit.  
 In order to meet the goal of maximizing health, quality prescription drugs must be 
fairly and equitably accessible.  Quality in this circumstance means a few different 
things; at its most basic, it means that the drugs on the market must be safe and effective, 
but in broader terms it could mean a duty to create innovative or the most effective drugs 
possible.  If taken in the broader sense, there is a responsibilty for innovation built into 
the requirements for an ethical pharmaceutical system.  This seems to be the 
interpretation favored by drug companies, and is often used to explain high prices. If 
companies are obligated to innovate, then they are justified in charging the prices that are 
necessary to fund that innovation. The second duty involved in maximizing health is the 
responisibility to make drugs equitably accessible.  This duty to equity encompasses the 
goals of accessabilty, affordabilty, and correcting for systematic disadvantage.   To 
accomplish these goals, vital drugs need to be affordable to everyone with no barriers to 
access such as limited suppliers or insufficient quantity.  Equity can also have a 
relationship with price discrimination, which is the practice of charging different buyers 
different prices based on their willingness or ability to pay.  In order to make drugs fairly 
and equitably accessible while maintainging profits a certain amount of price 
                                                        
24 Ibid.   
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discrimination may be necessary; but price discrimination should be used in order to 
lower what the poorest and most vulnerable pay, not to take advantage of those who lack 
barganing power.  Here we reach our first problem in justifiying pharmaceutical prices.  
If the pharmaceutical industry is producing good quality, life saving, innovative drugs, 
but charging prices that are unnaffordable, how can they be justified? What is the highest 
priority? It seems fair to say that if one is able to achieve the simultaneous goals of 
quality and access then one should be required to do so.  Thus, if companies do not need 
to charge high prices in order to create quality drugs, than they would not be justified in 
pricing people out of their treatments.  However, if high prices are necessary in order to 
create quality treatments, than the pharmaceutical industry would be justified in charging 
a lot, even if it meant that some or even most could not afford it.  If this is the case, we 
might hope or expect that some other payer, like private insurance, government insurance 
or charities might step in to help those with lower incomes afford necessary treatment; 
but it would not fall to the company to sacrifice quality for accessibilty.  However, this 
rests on the supposition that the quality of medication requires high prices.   
 After considerations of quality and equitable access comes the goal of fairness.  
Fairness can mean many things, but in this investigation will be used to describe access to 
the conditions and information necessary for patients and buyers of pharmaceuticals to 
make informed decisions.  Liberty and autonomy are wrapped up in this definition of 
fairness, because fairness is necessary for people to make free and autonomous choices 
concerning their healthcare.  In order for a pharmaceutical system to ensure liberty and 
autonomy for consumers there must be adequate information about drugs being sold. 
Patients, doctors, hospitals, insurers, and the government are all buyers of 
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pharmaceuticals, and are all entitled to sufficient information about the quality and cost 
of the products they wish to buy.  This information might be about the efficacy of a drug, 
the treatment alternatives, the list price and the cost breakdown.  A just pharmaceutical 
system must make this information available to consumers.  Finally, in order to achieve 
the ethical goals outlined above, profit is a necessary pragmatic goal in the US 
pharmaceutical system.  Without sustained profits for companies, they could not continue 
to produce drugs and no one would have access to the drugs they make.  However, while 
it is true that it is in everyone’s interest to ensure that pharmaceutical companies are 
making enough profit to stay in business, that does not mean there is an obligation to pay 
high prices beyond what it takes to create good quality and widely available drugs.  
 Some of these goals are not so different from most other consumer industries; in 
most purchases, whether it is cars, phones, groceries or clothes, there is a similar balance 
to strike.  There is an expectation of safety, effectiveness, affordability and profit in all 
industries.  However, what makes pharmaceuticals and other health industry purchases 
different is that the stakes are so much higher for consumers; it is not like buying a new 
phone (no matter what certain representatives in Congress might think) because going 
without a phone because of its cost is inconvenient but not fatal25.  When 10% of 
Americans have faced the decision to delay or forgo taking their prescriptions because of 
                                                        
25 Simpson, Ian. "U.S. congressman stirs backlash over healthcare versus iPhone comment." 
Reuters. March 07, 2017. Accessed April 04, 2017. http://www.reuters.com/article/us-usa-obamacare-
iphone-idUSKBN16E2RM.  
In March of 2017, amidst the debate over repealing and replacing the Affordable Care Act, 
Republican Congressman Jason Chaffetz, a proponent of the new bill, made some insensitive comments 
about American healthcare tradeoffs.  In recognizing that the bill would raise healthcare costs for many 
Americans (it would take away insurance from many and eliminate many of the federal subsidies for low 
income Americans buying insurance), he commented that poor Americans would have to decide between 
buying a new iPhone and buying health insurance.  
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cost, that is a much greater problem than if 10% are going without the latest iPhone26. 
There already exists an intuition in our own country (though it is less developed than in 
single payer countries) that no one should be turned away from accessing care; hospitals 
cannot turn patients away if they lack money or insurance, and we have many different 
systems for providing healthcare for those who cannot afford it.  So it does not seem that 
there is a strong belief that the poor or the uninsured or the very sick should be deprived 
of health services; rather, there are different strategies for improving access.  What 
further distinguishes the pharmaceutical and broader health industries from other 
consumer products is the fact that the buyers of the products are often not the consumers.  
With our complicated network of stakeholders, which ranges from the government to 
private insurance to private pharmacies to individual patients, the person making the 
purchasing decision is rarely the patient alone and so conflicts of interest are bound to 
arise.    
 After we consider how well the pharmaceutical industry is meeting its goals we 
need to answer the question of who is responsible for costs.  Responsibility can refer to 
blame for the state of high prices, but also the duty to remedy the problem.  In this ethical 
investigation I will touch on the aspect of blame, but will to focus on the duty to act. 
After determining whether the prices for drugs are justified, I will set out to find who is 
responsible for bringing down costs and making drugs more equitably and fairly 
accessible.  We cannot assume that drug companies are solely responsible for bringing 
down prices, because profit is an intrinsic goal of any company and because they were 
not alone in creating the problem of inequitable access.  While it is drug companies that 
                                                        
26 How does cost affect access to care?" Peterson-Kaiser Health System Tracker. November 29, 
2016. 
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set prices, they did not create the income inequality that causes differing abilities to pay, 
so they might argue that it is not their responsibility to make drugs available to the poor 
and uninsured.  However, if the prices they have set are unjustifiable and they could 
create quality drugs that are affordable while still making a profit, then they are not 
justified in raising prices to make their products inaccessible.  Furthermore, it is not very 
realistic for a company providing such a vital service to ignore the economic 
disadvantages that do exist. If water companies raised prices and cut off the water of low 
income Americans, we would not settle for the explanation that it is income inequality 
and not high prices that are causing the water to be shut off.   While income inequality is 
certainly a problem that should be addressed, it is hard to see how high prices on essential 
services do anything to alleviate that problem or the hardships people with low incomes 
face.   It seems that pharmaceutical companies cannot avoid all responsibility for the 
inaccessibility caused by high prices, but their responsibility for ensuring greater 
accessibility might be shared. Again, eliminating income inequality is not the most 
expedient means of increasing access to pharmaceutical treatments, but income inequality 
is clearly exacerbating inequitable access to drugs.  So who is responsible for increasing 
equity? The government certainly has its share of responsibility, and has acknowledged 
that responsibility through programs like Medicaid and Medicare.  Individuals by 
contributing to government and charitable programs have similarly accepted a 
responsibility to improve access.  So there are many stakeholders with responsibilities to 
improving access, and these responsibilities are rooted in both individual and collective 
interests.  Individually it is in the interest of most of these stakeholders to make drugs 
more widely available.  The government and taxpayers would benefit from lower prices 
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since it would lower their health expenditure while improving health. Individual private 
expenditure (co-pays, deductibles, and premiums) would be lessened if prices were 
lowered, and more people had access to affordable medications.  The interest of the 
pharmaceutical industry in making drugs more affordable is the least obvious, but it is 
still present. Pharmaceutical companies have one of the lowest approval ratings of any 
industry, even lower than oil companies, with only 12% of Americans holding a 
favorable view of pharmaceutical companies27.  Most Americans do not see drug 
companies as making significantly greater contributions to quality of life than any other 
industry, but they do see them as making too much money and being too focused on 
profits28.  Taking greater action to make drugs more affordable would not only be a more 
sustainable model, but would improve the image of companies tremendously.   
 In addition to these individual or self-interests in improving pharmaceutical 
access, there are also collective reasons why improving access to drugs is a worthy goal.  
While lowering costs would be financially beneficial for everyone, it would also improve 
the health and lives of those currently struggling to afford their medications.  While the 
goals of health industries are articulated through quality and access, the overall goal is to 
improve health.  We have a responsibility to each other and to our collective health.  We 
saw from the statistics on life expectancy, mortality and morbidity, that we are not doing 
a great job of improving the health of our fellow Americans compared to other nations.  
Whether we look at these aggregate statistics of health or at the rates of people who 
cannot afford medications or at the stories of individuals who struggle to afford 
healthcare, it is clear that any collective duty to protect the health of others is being 
                                                        
27 Brodie, Mollyann, Jamie Firth, and Bianca DiJulio. "Kaiser Health Tracking Poll: August 
2015." 
28 Ibid. 
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shirked.  But again a problem arises in pinpointing where the responsibility lies in 
making drugs affordable when there are so many stakeholders.  
 In order to investigate pharmaceutical pricing and access and to determine 
whether the prices charged are justifiable, we must evaluate how the industry and our 
pharmacy benefit system measures up against the goals and responsibilities outlined 
above.  This will require both empirical and ethical evaluations of the actions of drug 
manufacturers, government entities and private insurers. Empirical evaluations are 
necessary to consider claims made by pharmaceutical companies that living up to their 
quality responsibilities requires high prices, which limit access.  Empirical evaluations 
are also necessary to understand whether the pharmaceutical industry is truly living up to 
its obligations to quality and fairness.  To accomplish these empirical and ethical 
evaluations I will use a case study method to understand the nuances of pharmaceutical 
pricing, the problems created by high costs and the justifications that may exist. The case 
studies I will employ are all drugs that have received media attention in the last year 
concerning their high cost.  While the drugs are all very different, they are all examples 
of drugs that have become cost prohibitive.  Some of the causes for their high prices 
overlap and so do some of the solutions, but they also present unique challenges and 
policy ideas.  The first case, EpiPen, is a unique pharmaceutical device that can save 
patients experiencing anaphylactic shock; yet in the last 10 years the price has gone up 
500%, not because of investments in the device, but because of investments in marketing 
and lobbying.  The second case, Hepatitis C anti-virals, are a very promising new class of 
drug with the ability to cure most patients with Hepatitis C; yet the high price tag has the 
potential not only to bankrupt individual patients, but Medicare and Medicaid as well.  
 12 
Finally, Multiple Sclerosis therapies are unique in that increase in competition among MS 
medications has led to an increase rather than a decrease in the cost of treatment.  With 
their various challenges, each case has shown the possibility for different policy 
solutions.  In reviewing possible policy interventions, I found very little evidence that any 
government or private regulation of drug prices would have a negative effect on quality 
of care or the price of pharmaceuticals.  While it is difficult if not impossible to predict 
what the exact outcome of any given policy would be, the risks of further regulating the 
pharmaceutical industry are not high.  On the other hand, the costs to the health of 
patients and the bank accounts of stakeholders are already great, and will only increase if 
no intervention is taken.  Unfortunately, many of the steps that I will suggest require a 
significant amount of political will that would be difficult to muster even in the most 
effective of political climates, but certainly will be even more difficult under the current 
anti-regulatory administration.  However, while many of the government solutions will 
not be possible until a shift in political priorities takes place, there are private and 
individual steps that can be taken to limit the negative effects of rising prices.  Public 
pressure and outrage have led to companies lowering prices or introducing generics, and 
the informed decisions of healthcare providers like doctors and hospitals to choose more 
cost effective options have also made an impact on drug expenditure.  While there are 
many challenges to achieving equitable access to drugs, there are a myriad of solutions.  
This variety can be daunting, and it is hard to say what the most effective solutions will 
be, but not knowing which path to choose should not stop us from moving forward to 
address the unaffordable cost of pharmaceuticals in the United States.   
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Chapter 1: Case Study on EpiPen Prices 
In 2015, 3.6 million Americans were prescribed EpiPen to assist in medical 
emergencies caused by contact with an allergen29.  Unfortunately, due to high costs, 
many Americans have to make difficult decisions about whether they can afford the life 
saving drug.  EpiPen is an auto-injector, which safely delivers a measured dose of 
epinephrine into the muscle tissue of an individual experiencing symptoms of 
anaphylactic shock.  While epinephrine (also known as adrenaline) has been used to treat 
anaphylaxis long before EpiPen, auto-injectors have become the safest and quickest way 
to deliver epinephrine, and are easy enough to use that patients and bystanders can inject 
the drug themselves30.  This was an important development in the treatment of severe 
allergies because, in cases of anaphylaxis, speedy delivery of epinephrine can save lives, 
and in many cases there is not enough time to wait for a health care professional.  While 
neither the drug itself nor the injection technologies are new, auto-injectors are so 
essential to those living with severe allergies, that EpiPen (which has a near monopoly on 
the auto-injector industry) has been able to steadily raise prices over the last 10 years 
without raising much concern31.   
Since 2007 when Mylan, a company that mostly produces generic drugs, 
purchased EpiPen, the cost has been rising steadily by about 20% per year.  In 2015, the 
                                                        
29 "Wyden, Pallone Question Mylan Payments to Medicaid for EpiPens | The United States Senate 
Committee on Finance." United States Senate Committee On Finance. September 02, 2016. Accessed 
October 04, 2016. https://www.finance.senate.gov/ranking-members-news/wyden-pallone-question-mylan-
payments-to-medicaid-for-epipens.  
30 Carroll, Aaron E. "The EpiPen, a Case Study in Health System Dysfunction." The New York 
Times. August 23, 2016. Accessed October 04, 2016. https://www.nytimes.com/2016/08/24/upshot/the-
epipen-a-case-study-in-health-care-system-dysfunction.html.  
31 Ibid. 
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price spiked to $600 for a set of two32.  While the price paid by individuals varies based 
on their health plan, the burden to the healthcare system as a whole is considerable.  
Between 2007 and 2014 average out of pocket spending for patients on EpiPen has 
increased from $34 to $75 with 18% of patients paying over $100 and 5% paying over 
$200 out of pocket33.  This is a significant burden for patients to bear, and one which is 
magnified when you consider than many patients may elect to buy multiple EpiPens to 
keep in the home, car, work/school, and bag, and magnified again because the drug 
expires after 12 months, requiring that the drug be replaced annually.  Even if an allergy 
patient has a great health plan with minimal co-pays, the $600 price tag is significant for 
insurers and can contribute to the existing problem of insurance premium increases.  
Furthermore, many of the buyers of EpiPens are government insurers like Medicare & 
Medicaid, or other tax funded institutions like schools and emergency services.  Overall, 
whether you have an allergy or not, everyone is helping to pay for the rising costs of 
EpiPens.   
This latest price increase has led many to question what the reason could be for a 
500% price increase over 10 years, when few improvements have been made to the auto-
injectors, and when the demand seems to be ever-expanding.  While Mylan has been very 
secretive about their contracts with their manufacturers and distributors, and unwilling to 
give a complete breakdown of their expenses, they have suggested that improvements 
like a retractable needle and better grip have resulted in a significant capital investment in 
                                                        
32 Damacio, Anthony, Tricia Neuman, and Juliette Cubanski. "How Much Has Medicare Spent on 
the EpiPen Since 2007?" The Henry J. Kaiser Family Foundation. September 21, 2016. Accessed October 
15, 2016. http://kff.org/medicare/issue-brief/how-much-has-medicare-spent-on-the-epipen-since-2007/.  
33 Rapaport, Lisa. "Another look at the surge in EpiPen costs." Reuters. March 27, 2017. Accessed 
April 04, 2017. http://www.reuters.com/article/us-health-epipen-costs-idUSKBN16Y24O. 
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the injector.  Critics wonder if these costs were truly high enough to require such extreme 
price hikes, and furthermore, if the changes were a significant enough improvement to 
make the increased cost worth it for patients.  Some critics believe that the only real 
capital investments Mylan has made in EpiPen are their advertising and lobbying 
efforts34.  Without any internal documents or data from Mylan outlining why the price 
increases are necessary, it is hard to believe that what seem like minimal changes could 
cause a 500% price increase over 9 years.  
Mylan CEO, Heather Bresch, was called by Congress to testify to the EpiPen 
price hikes, but in her testimony, Bresch was not very forthcoming about the cost of 
EpiPen.  She has stated that she cannot disclose the details of Mylan’s contracts with 
manufacturers and distributors due to confidentiality agreements.  While confidentiality 
agreements are common among business partners, when there is such a public risk 
associated with rising healthcare costs it seems that more transparency might be 
necessary.  Bresch continues to play her cards close to her vest, but has made claims that 
it costs about $69 to make 2 EpiPens. Independent estimates have produced slightly 
different findings; one study concluded that one EpiPen likely only cost $30 to make, or 
$60 for the pack of 235.  While this difference is not huge, the difference between both 
estimates and the $600 price tag certainly is.   
Besides the mystery around the true cost of EpiPen, there is also some 
controversy over how much Mylan makes off each injector.  Bresch has stated that the 
                                                        
34 Coy, Peter. "The EpiPen Drama Shows What's Wrong With How Drugs Are Priced." 
Bloomberg.com. September 01, 2016. Accessed October 04, 2016. 
https://www.bloomberg.com/news/articles/2016-09-01/the-epipen-drama-shows-what-s-wrong-with-how-
drugs-are-priced.  
35 White, Martha C. "It's Jaw-Dropping How Little It Costs to Make an EpiPen." Money. 
September 07, 2016. Accessed October 04, 2016. http://time.com/money/4481786/how-much-epipen-costs-
to-make/.  
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$300 rebates they give to insurance companies cut into their profits significantly and that 
after rebates and fees Mylan only make $274 per pack36.  She further states that other 
unnamed fees bring the profits down to about $100 per pack ($160 pre-tax)37.  Without a 
rigorous account of Mylan’s expenses and costs, it is hard to know whether we can trust 
this account. Ronny Gal, a pharmaceutical industry analyst at the investment firm 
Sanford Bernstein, says Mylan may make a 40 percent profit margin on the EpiPen, and 
that is a conservative estimate38.  Critics might claim that demanding a 40% profit margin 
off a ubiquitous but life saving drug is highway robbery, especially when one considers 
that the 40% profit is likely what is made after the maximum number of rebates and 
discounts are offered, and there are likely many EpiPens sold where the profit is far more 
than 40%.   
EpiPen is not the only drug that has steadily or suddenly increased its prices in the 
last few years, but many factors make it an interesting case study in the ethics of drug 
pricing.  In order to evaluate the ethics of EpiPen’s price, we must compare it to the 
framework we have established.  In order for a $600 price to be justified, EpiPen must be 
a quality drug that is both equitably and fairly accessible. Ethical problems involved in 
the EpiPen controversy include questions about the justness of patent law, the use of 
marketing and lobbying by “big pharma”, the secrecy with which it operates, the 
relationship between drug companies and insurers, and their proposed release of a generic 
version of their own product. EpiPen is a safe and effective drug, but is hardly a recent 
innovation; yet it remains under patent protection and consumes a 93% market share in 
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auto-injectors39.  Innovation is rewarded and protected by patents, which offer market 
exclusivity for a limited period, so investigating the quality, and accessibility of a drug 
requires an evaluation of patent protection.  First, the market exclusivity offered by 
patents allows companies to charge whatever they please with little ability for patients, 
insurers or the government to contribute to the determination of a good price.  Second, 
patents allow companies to sue competitors who attempt to introduce competing drugs on 
the basis of patent infringement, and even if the competitor would or could win the 
challenge the expense and delay allows the first company to maintain their exclusivity40.  
Third, in the case of EpiPen, which is a medical device, not a drug, there are concerns 
that it is not really worthy of continued patent protection.  Fourth and finally, the 
argument for patents is that they encourage innovation and allow companies to recoup the 
losses they sustain during drug development, but there is an argument to be made that this 
system is not working out as intended and that the current patent system is actually 
hindering innovation.  
Critics have accused Mylan of taking advantage of the limited competition in the 
market for epinephrine auto-injectors by raising prices before their patent expires and 
generics begin to compete. EpiPen will be under patent protection until 2025, meaning no 
other company can replicate its design until then41.  Furthermore, any company that 
attempts to patent a new design could face litigation from Mylan if they believe the new 
product too closely resembles theirs.  This has led to EpiPen taking up a 93% market 
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share42.  This near monopoly is made possible by the patent protections that the US 
government offers Mylan and other drug companies.  The idea behind these temporary 
monopolies is to allow drug companies to make up for capital losses incurred in the 
research and development of new drugs, and to protect intellectual property and 
encourage innovation.  Most companies, including Mylan, argue that while their prices 
are often high, they provide great value, and customers are willing to pay a lot for that 
value.  In an August 2016 interview, Martin Shkreli (also known as Pharma Bro) actually 
argued that the $600 price tag on EpiPen is a great value for both patients and insurers 
because of the life-saving and potential cost saving affects of the drug43.  While it is true 
that EpiPen can save lives and limit some of the most serious symptoms of anaphylactic 
shock, most cases where an EpiPen is used also require a hospital visit and even an 
ambulance ride, which possibly limits the effectiveness of down-the-line cost savings as 
an argument for the high price tag.  However, even if we were to acknowledge that it is a 
drug with life-saving and cost-saving capability, it must also be acknowledged that many 
people cannot afford to pay $600 a year for EpiPens, so whether the responsibility lies 
with Mylan to lower costs or with insurers to improve benefits, the problem remains that 
individuals cannot afford the drug.  
Besides the value of their products, companies often argue that while patents are 
what allow them to have temporary monopolies at all, the process for obtaining market 
access and exclusivity are also to blame for the high prices.   Drug companies might 
argue that the reason they must charge so much and increase their prices so often is that 
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the window of exclusivity they have is too short, and they can’t make a significant 
enough profit in that time to satisfy their shareholders if they charge a price that 
consumers would consider fair.  Currently, patents last twenty years and take effect as 
soon as the drug is invented44.  This seems like a long time, but the FDA approval 
process is also very long, often eight and sometimes 12 years, and during that time the 
exclusivity clock winds down while the company sees no profits.  This would be 
understandably frustrating as an executive of a pharmaceutical company and may have 
trickle down effects that limit investor confidence in drug research and thus limit 
innovation.  But does it justify the price spikes that patients endure? While EpiPen is a 
quality drug in its safety and effectiveness, it is unaffordable for many Americans, and 
this is unjustifiable if the high price is not a necessary cost of ensuring quality. EpiPen 
has had patent protection for a long time and will continue to have it till 2025; it has long 
since paid for itself and any losses incurred during its development, and yet prices remain 
high and Mylan’s profits continue to grow.  While there may be an argument that high 
prices are necessary to recoup losses, they cannot be justified indefinitely, nor can price 
increases be justified once profits exceed the initial loss.  Therefore, it seems that the 
price of EpiPen is unjustifiable and patent protection is playing a part in allowing the 
unjustified prices to continue. 
However sympathetic one might be to the “plight” drug companies face in waiting 
for approval from the FDA, one could counter that not all products deserve the 
exclusivity they are granted, and furthermore that drug companies use very shady 
practices to maintain their exclusivity.  In the case of EpiPen, the product that is licensed 
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is not epinephrine but the auto-injector.  There are several factors that can call into 
question whether EpiPen deserves the protection it has.  To start, the patent for EpiPen is 
for the design of the auto-injector and for the stabilized epinephrine solution.  The 
injector design, while technically unique, is not completely novel; it was based on a 
1970s design for an auto-injector that is used by the military to deliver anti-nerve gas 
serums to soldiers affected by chemical weapons45.  The company that still manufacturers 
those injectors is contracted by Mylan to manufacture the EpiPen.  So at the time of its 
creation the EpiPen was no more innovative than some of the competing injectors that 
have been prevented from reaching the market today.  The fact that the EpiPen is 
primarily a medical device, not a drug, is significant because it is actually more difficult 
to improve upon or redesign without appearing to be stealing designs.  If it were just a 
drug, than one could prove its uniqueness by the chemical formula, but devices are much 
harder to prove to be novel.  This makes introducing competition to the auto-injector 
market more difficult and actually stifles innovation.   
There may be some problems in determining what novelty in a medical device or 
drug means, but there are really no restrictions on the ability of drug companies to sue 
companies that attempt to patent or gain market access for competing products. While 
drug companies claim that they deserve market exclusivity because of their innovation 
and the value of their products, and while they accuse the process of getting FDA 
approval to be too long and costly, they spend their money and the taxpayer’s money on 
long legal battles to prevent innovation and competition from other companies. While 
companies need to be able to defend their intellectual property, there must be more 
intervention on the part of the government to prevent trivial lawsuits.  If companies could 
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just copy old drugs and products and sell them, that would set a dangerous precedent and 
could easily harm the pharmaceutical industry and its ability to draw investors in 
innovation.  However, trivial suits set the same dangerous precedent; they make it 
impossible for viable competitors to enter the market because any new drug, even if it is 
truly novel, could face a legal challenge if it treats the same condition as another drug.  
Currently, even if a suit fails and the new drug is determined to be novel, there is no legal 
or financial consequence to the company that challenges the new drug, except the sunken 
costs of the suit, which may be worth it to the company if it has delayed the new drug 
entering the market46. Mylan has prevented other auto-injectors from entering the market 
through such lawsuits, and while it is difficult to say whether they were right about their 
claims of copyright infringement, the effect has been that there is no competition for 
EpiPen and they can set their own prices47.   
I have described many problems with the patent system, both in the eyes of drug 
companies and on behalf of consumers.  Essentially, drug companies argue that they need 
longer lasting patents in order to make enough off their drugs to recoup losses from 
development and satisfy shareholders.  These points are unconvincing for a lot of 
reasons. First, the global pharmaceutical market is worth $300billion, so companies make 
enormous profits and clearly are creating returns for shareholders48.  Second, it is hard to 
see a direct connection between increasing profits and increasing innovation, the most 
profitable drug on the market is Lipitor, which is one of many cholesterol-lowering drugs 
                                                        
46 Angell, Marcia. The truth about the drug companies: how they deceive us and what to do about 
it. Melbourne: Scribe, 2006. Pp.  
47 Keshavan "5 reasons why no one has built a better EpiPen." (2016) 
48 Gross, Terry, and Elizabeth Rosenthal, writers. "How U.S. Health Care Became Big Business." 
In Fresh Air. National Public Radio. April 10, 2017. April 10, 2017. Accessed April 12, 2017. 
http://www.npr.org/sections/health-shots/2017/04/10/523005353/how-u-s-health-care-became-big-
business.  
 22 
and has not been proven more effective than any of the others49.  Yet, while the 
connection between profits and innovation is dubious, we allow drug companies to set 
their own prices unchecked for the duration of their patent life. Furthermore, profits and 
private investors are not the only ones sponsoring pharmaceutical research, the Federal 
Government provides $32billion annually to fund medical research50.  It seems counter-
intuitive that the people should fund innovation, then be asked to pay high prices in order 
to pay back investors.  We all have an interest in seeing innovative drugs developed, and 
it is great that there is both private and public investment in those innovations.  But it 
seems that if the government is such a large investor, they should be seeing returns on 
those investments, either in the form of lower prices or dividends on profits.      
An upshot of market exclusivity is price setting, which leads to price 
discrimination, meaning that while they have one list price, they can provide different 
discounts or rebates to different customers.  By practicing price discrimination companies 
are able to charge high prices to those who can afford it, or those who are unable to 
bargain (Medicare) without loosing access to markets where customers cannot afford or 
won’t pay such high prices.  This occurs on an international level with drug companies, 
including Mylan, charging different prices in different countries, and this practice has led 
to the United States paying more for drugs than any other country in the world.  But this 
price discrimination also occurs within the United States, because companies like Mylan 
negotiate with each buyer separately and can provide different sized rebates to each 
insurer.  Furthermore, while the rebates they provide may not be enough to allow every 
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patient to access the drug, they can still provide individual discounts to patients based on 
income.  While providing discounts to poor patients should be a sign of positive price 
discrimination that improves access, in general, the process of price discrimination means 
that companies can extract every available penny from the healthcare industry.   
In order for price discrimination to be justifiable in the pharmaceutical industry, it 
must enhance rather than hinder equity of access. Thus, price discrimination should not 
just allow private groups to bargain for lower prices, but should actively seek to ensure 
that the most vulnerable pay the least for drugs.  What is notable about price 
discrimination in the United States is that while those without insurance may receive 
discounts from manufacturers, Medicare and Medicaid, which insure the elderly and the 
poor respectively, often end up receiving the worst deals in price negotiation.  In the case 
of Medicare, this is because they are unable to bargain for lower prices at all, and in 
Medicaid because it is managed differently in each state and lacks strong support from 
the federal government.  Despite the difficulties in negotiating lower prices for Medicare 
and Medicaid, it would seem that there is a positive duty on behalf of manufacturers to 
ensure that these programs have access to a low price for drugs, at least as low (if not 
lower) than the prices negotiated by private insurers.  But what happens all too often is 
that these government programs, which represent the most vulnerable segments of our 
population, pay the highest prices for drugs.  Prices are not justifiable if their price 
discrimination disadvantages the vulnerable, and when this is the case the positive 
responsibility to take action lies with the drug company to use negotiation tactics that are 
more equitable.    
 24 
While the price discrimination practiced by drug companies is unjustifiable, 
companies would naturally resist the idea of price regulation, perhaps arguing that the 
forces effecting drug prices are varied, complex and dynamic, and setting a price cap 
would not allow the industry to be responsive to changes.  It seems fair to say that there 
are factors that lead to price fluctuation, but there is no evidence that the dramatic price 
increases we have seen across the medical industry due to “changing market forces.”  
Rather it seems that the dramatic increases are due to the industry being allowed to 
regulate itself.  In the case of EpiPen the only fluctuation that seems to appear in their 
costs is the dramatic increase in advertising, lobbying and information campaigns.  
Furthermore, it may be that Mylan purposefully chose the beginning of the school year as 
the time to raise prices as both students and schools were stocking up for the year.  This 
is especially problematic when we consider the extensive effort Mylan made to lobby the 
federal government to encourage schools to stock EpiPens.  
Mylan has recently succeeded in getting a federal law passed to provide funding 
for schools to stock EpiPens, as well several state laws that mandate EpiPens be carried 
in schools51.  In theory this would be a noble goal that expands access to a life-saving 
drug, but in practice it is a means Mylan secured a legal mandate for more customers to 
purchase their product before jacking their prices up further.  In a way, Mylan has pulled 
the wool over the eyes of legislators, lobbying them to mandate that the product then 
raising the prices once the schools, which are already underfunded in most districts, 
cannot opt out.  Furthermore, Congress passed the law with a certain budget in mind, and 
that budget will not stretch as far now that the prices have increased.  What adds insult to 
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injury is that Mylan cites their lobbying efforts as justification for their price increases52.  
Mylan executives do not deny that their lobbying efforts were a major expense and may 
be a part of the price increase, but they do not seem to see the worry that crops up when a 
private corporation convinces the government to encourage or even require the purchase 
of their product and then increases the price. Mylan might argue that they provided a 
public service in expanding access, and relieved some of the burden on families to have 
multiple pens for their child, because at least the school would always have one.  But by 
raising their prices they limit the good this program could have done, by increasing the 
burden for already strained school budgets and increasing the burden for families, who 
still need to buy a pen for their child for when they aren’t at school. To compensate for 
that, Mylan gave out thousands of free EpiPens to schools after the new law was passed, 
in response to the high prices. But providing some EpiPens for free does not make up for 
the damage done by the extreme costs to the school and health systems caused by their 
price increases. 
Perhaps the public should be expected to take on all the costs of bringing EpiPens 
into schools because it is a public good that the government should have seen to without 
Mylan’s lobbying.  After all, Mylan wasn't the only group advocating for more awareness 
of anaphylaxis and greater availability of EpiPen.  The Food Allergy Research and 
Education group (FARE) also supports greater availability of EpiPen, but Mylan is a 
significant donor to FARE, so can the public trust their recommendations?53 Overall, 
giving out EpiPens to schools and providing savings cards to low and middle/low income 
Americans do not necessarily improve access, because they may exclude as many people 
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as they include, and the measures only help if they offer them year after year, and if they 
don’t continue to raise their prices. Mylan might say that the $600 price is “worth it” to 
consumers, insurers and taxpayers, but just because a drug is “worth” a certain price, 
doesn't mean that that price is fair, especially when those prices are coming out of patient 
pockets.  Many people may say that EpiPen is “worth” the $600, but if they don’t have 
$600 its worth doesn’t matter because they simply can’t afford it.  Mylan’s spending on 
advertising, lobbying and even their “charitable” gifts to non-profits, call into question 
whether consumers are being given the opportunity to make informed decisions about 
their health.  If government decisions are being influenced by lobbying, and public 
opinion is being swayed by advertising and EpiPen subsidized education campaigns, then 
it is difficult to say whether consumers are able to make informed choices.  Add to that 
the opacity of Mylan’s communications about their costs, and the public has virtually no 
trustworthy information about EpiPen.   
In addition to their suspicious practices in lobbying the government, Mylan and 
other drug companies have participated in creative but questionable bargaining practices 
with insurance companies.  Mylan offers $300 rebates to many insurance companies who 
include EpiPen in their formularies, which raises questions about whether the insurers 
have any interest in lowering prices, and about why the prices would be so high if the 
private insurers all pay less54.  The answer may be that because Medicare cannot bargain 
for lower prices, taxpayers and the elderly may be paying the $600 sticker price when no 
one else is.  These rebates are suspicious because they suggest that there really is no 
reason for the $600 price tag, except for the fact that Mylan has nothing stopping it from 
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charging as much as they want, since there is a costumer (Medicare) who will have to pay 
whatever price they are offered. What is further disturbing and implicates insurers in 
rising costs, is that despite the rebates given to the insurers, many patients still have high 
out of pocket costs, suggesting that insurers are not passing their savings on to customers.  
These deals between insurers and drug companies are also problematic in the exclusivity 
of the deals that are made.  If these bargains were not struck, one could argue that 
EpiPen’s competitors may have had an easier time gaining market share.  As it stands, if 
an insurer wishes to pay less than $600 they most likely have to agree not to cover non 
EpiPen auto-injectors55.  It seems that there should be a shared sense of responsibility for 
setting fair prices, and insurance companies should allow their customers to retain their 
choice of drugs and treatments, especially where cost differences exist.  
 Many problems associated with drug pricing and drug company practices, 
including Mylan, are difficult to really parse out because of the secrecy under which the 
industry operates.  Even when called in to testify for Congress, Heather Bresch refused to 
give the full picture of the costs of manufacturing and selling EpiPen, or the deals made 
with insurers.  This cloud of secrecy makes it very difficult to fully understand the true 
reasons for rising drug costs and thus makes it difficult to determine for certain whether 
prices are ethically justifiable.  This opacity must be cleared if we are to get an accurate 
picture of drug pricing ethics.  Furthermore, while the opacity makes it difficult to 
understand the drug pricing landscape, it also suggests fishy practices on the part of 
pharmaceutical companies. The lack of information is a problem because it hinders our 
ability to answer some of our ethical questions about the fairness of prices being set, but 
it is also an ethical problem in itself.  We do not only want to know about the workings of 
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Mylan in order to know whether they are up to no good, we also just have a right to know 
what we are paying for, and to make informed decisions about all our purchases.  This 
right to make informed decisions is even more important in health industries, because of 
the high stakes for patients and high costs to consumers.   
 All of these ethical questions have been raised since the last price increase of 
EpiPen, and in response to the public outcry about the unreasonable cost Mylan has 
decided to release a generic version of the EpiPen.  While it is certainly a positive step 
that the company felt the need to take steps in response to the public outcry, their 
decision to release a generic to compete with their own product is an interesting one, and 
may have further effects on price discrimination.  Once they release the generic, which 
will be completely identical to EpiPen except for the label, Mylan plans to list it at $300 
for a pack of two.  But the question is why not just lower the price of the brand name to 
$300, especially since that is already the price most insurers pay after rebates? There has 
been some speculation that releasing a generic will actually have very little impact on the 
cost of EpiPens, because insurance companies will continue to cover the brand name with 
the old rebates, or will purchase the generic for the same price56.  The offer of a generic 
may have an effect on Medicare because their lack of bargaining power may mean that 
they have paid the most for brand name EpiPens, but again because of the secrecy of the 
industry we do not know who pays what.   
Throughout this case study, several key questions arose that will relate to future 
case studies, and to the overall goal of determining whether the prices we pay for 
pharmaceuticals are justified.  Mylan is certainly not the only company to take advantage 
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of market exclusivity, and it may not be right to place blame on them for trying to make a 
profit when that is their goal as a private company.  However, the way in which Mylan 
and other companies use market exclusivity is wrong, and we should not allow them to 
set their own prices without the regulation of government or competition.  This seems at 
least in part to be because of a lack of reciprocity between the pharmaceutical companies 
and the public, the public provides patent protection so the pharmaceutical companies 
should be paying them back by not charging exorbitant rates, or at least not by wasting 
public resources with long legal battles to extend exclusivity.  Another issue of 
reciprocity seems to be in the issue of research and development, prevailing studies seem 
to indicate that drug companies spend much more on money on advertising then research 
(this is certainly the case with EpiPen), while the NIH takes on the risk of investing 
billions in innovation.  Without diving into the complex slew of ethical issues associated 
with drug marketing, it is clear in the case of EpiPen, the public is being charged 
repeatedly for the same product: first through the taxpayer dollars funding innovation, 
Medicare and Medicaid, second through health insurance premiums and third at the 
pharmacy counter.  In order for the price of EpiPen to be justified, it must match the 
criteria established; it much be a quality product available to all at prices they can afford 
that allows for both consumer choice and corporate profit.  EpiPen is a quality product 
that saves lives, but its price makes it unaffordable to many Americans and places as high 
burden on individuals and insurers (particularly the most vulnerable).  Furthermore, the 
high prices are not necessary for recouping any losses sustained in improving the quality 
of EpiPen, because the prices have been going up even when no changes had been made.  
Additionally, the secrecy under which Mylan operates and their marketing and lobbying 
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efforts have limited consumer choice and obstructed the right of patients and consumers 
to know what they are paying for.  While the prices charged by Mylan are not justifiable, 
there is a shared responsibility for bringing down costs.  Mylan certainly takes the blame 
for taking advantage of market exclusivity to set high prices, practice unfair price 
discrimination and hiding information from the public, but private insurers, the 
government, and individuals also must accept responsibility for bringing down costs. 
After reviewing all of the case studies, I will show what policies can be implemented by 
all of these groups to lower costs.   
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Chapter 2: Case Study on Hepatitis C Treatment Costs 
Hepatitis is a tricky disease to nail down, some estimate that between three and 
five million Americans are infected, but only half know it.  This is because Hepatitis can 
lay dormant in the body for decades, or present itself with flu-like symptoms early on.  
Around a quarter of those affected by the disease have it for only a short time because 
their bodies fight it off on their own.  Most people infected with Hepatits, about 2.7 
million Americans, develop chronic Hepatitis (Hepatitis C or Hep C).  Hepatitis C has a 
spectrum of severity within itself as well as a six distinct virus strains.  Chronic Hepatitis 
can also start with flu symptoms, but down the line can lead to chronic liver disease, 
cirrhosis of the liver, and liver cancer. Hepatitis is a blood borne illness and most patients 
develop it through injected drug use, or from blood transfusions received prior to 1992 (at 
which time a screening test was developed to detect Hepatitis) 57.  The connection 
between Hepatitis C and injected drug use creates many problems for treatment, because 
patients may be disconnected from health care, they may face stigma in trying to access 
care, and if they are uninsured they may not be able to afford it.  Furthermore, there are 
some concerns that even when Hepatitis patients who use drugs receive treatment they do 
not follow through.   
Treating Hepatitis C has always been costly, even before anti-viral treatments 
were available, the cost of treating the long-term liver damage can be millions of dollars 
for just one patient.  Early anti-viral drugs attempted to curb these costs and the harm 
done by the disease by attacking the virus before it can cause too much damage.  These 
early anti-viral medications were administered intravenously in hospitals, so it was very 
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difficult for patients to keep up with the treatment.  Furthermore, they were not very 
effective, safe nor cheap.  Since 1991, when the FDA approved the first Hepatitis C 
treatment, advances have slowly been made to improve the quality of life and health 
outcomes for Hep C patients.  At the start, even with treatment there was very little 
chance of clearing the infection.  Most treatments were administered intravenously in 
hospitals and were prescribed only to those who had already developed liver disease.  
The necessity of getting to a hospital and possibly remaining there for long stretches of 
time was a significant burden for patients, especially those who suffered from drug 
addiction or were uninsured.  Treatments before 2013 were not recommended for patients 
suffering from HIV co-infection or liver cancer nor were they effective across the 
spectrum of Hepatitis C genotypes.58   
Since 2013, treatments have become safer, more effective and more widely 
usable—across multiple Hepatitis genotypes, in patients with co-infections like HIV and 
during many stages of disease progression.  In 2013 the first oral medications for Hep C - 
Sovaldi and Olysio - were approved, making treatment easier for patients to obtain and 
keep up with; however these treatments were still recommended in conjunction with 
intravenous, hospital-administered medication.  While these medications made dramatic 
steps in efficacy and in the spectrum of patients that could be treated, fully outpatient care 
was still out of reach for another year.  In 2014, Harvoni and Viekira Pak were approved 
by the FDA as fully oral regimes; however they are only shown effective in patients with 
Hepatitis C genotype 1 and not for patients with co-infections.  In the next year other oral 
treatments were introduced to treat Hepatitis C genotypes 3 and 4, but in 2016 the first 
drugs designed to treat the full spectrum of Hepatitis genotypes are approved.  These 
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drugs - Zepatier and Epclusa - are all oral, single tablet regimens, which after 12 weeks 
see 94-100 percent of patients’ virus free. For patients fighting Hepatitis, these drugs 
could be life-saving and come with both more guarantee of success and less commitment 
from the patient59.  However, while these new drugs truly solve some of the pressing 
issues of Hepatitis C treatment, and reduce some of the costs associated with hospital 
administered treatment, the cost of these drugs is still very high and is causing major 
problems for both individuals and providers.   
With the greater efficacy, broader use and ease of new treatments comes higher 
demand.  More and more people with Hepatitis C are looking for a cure, but due to the 
high cost of the treatment providers are worried about the increased costs.  Since 2014, 
new Hepatitis C medications have led to a 13.1% increase in prescription drug spending 
nationally and the Center for Medicare and Medicaid services estimates that the demand 
for and cost of Hep C drugs will lead to an additional $65 billion in spending over the 
next 5 years in comparison with previous treatments60.  These costs are staggering, but 
are not surprising given the $54,000-$94,000 price tags.  It is certainly shocking when 
Zepatier can advertise itself as a bargain at $54,000 for a 12-week course because their 
biggest competitor Epclusa costs $74,000.  To be fair, compared to the costs the last 
generation of Hepatitis C medications (Harvoni costs an average of $94,000 per course), 
the newer generation does save money61.  This is further true when we factor in the cost 
saving associated with reduced rates of liver disease (a liver transplant can cost $700,000 
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for the surgery alone)62, but in the short term costs are going way up because of the 
increased demand for the improved drugs.   
The increase in demand is significant and has many causes; the newer drugs are 
more effective, have fewer immediate side effects and are less cumbersome as they 
generally consist of a once daily pill.  Furthermore, previous generations of treatments 
have been unavailable and unusable for broad spectrums of the Hepatitis C infected 
populations.  Previous generations of drugs were only effective on individuals at specific 
stages of liver disease caused by Hepatitis C, and not available to those with HIV co-
infection.  Because the newer drugs are usable by broader spectrums of the Hep C 
positive population, the demand, and thus cost, is going up.  This has caused rationing on 
the part of insurers in order to limit the amount of patients eligible for the new drugs.  
Many insurers have decided that in order to receive these drugs a patient must have liver 
disease diagnosed by biopsy63.  This means that many patients who are Hep C positive 
are not eligible for treatment until they are experiencing liver disease which may have 
painful symptoms and which must be diagnosed through a somewhat dangerous 
procedure.  Some exceptions to these rationing rules can be made in cases where co-
infection can increase the risks associated with liver disease or biopsy, such as kidney 
disease or HIV, but overall it seems that there are some serious problems caused by the 
costs of Hep C medications.   
The prohibitive costs of Hepatitis C drugs are problematic for one major reason; it 
forces a decision for healthcare providers in which they must choose between the prime 
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objective of doctors to improve health and prevent illness, and the necessity of having a 
sustainable healthcare system that can continue to treat and support patients for years to 
come.  The position that the prices of Hepatitis C drugs put us in is one where we must 
decide to prevent and fight liver disease by attacking its cause—Hepatitis C—but in 
doing so bankrupt our healthcare system.  This is an impossible situation because 
whatever the choice, the outcome means that patients will not receive treatment, whether 
now or in the future.  
While insurance companies and doctors state the need to lower the costs to treat a 
wider range of patients, drug companies state that the prices they have set for their 
products are fair.  Many of their reasons are similar to those we have heard from Mylan 
and other drug companies, which is that the innovation of their company comes at a 
price.  This argument is more compelling in this case than in Mylan’s, because we can 
see from the progression of Hepatitis C treatments that these newer drugs are better than 
what has come before, and the research needed to develop them may well have been 
expensive.  On their last drug to treat Hepatitis C – Harvoni—which costs over $1000 per 
pill, Gilead industries made $18 billion in 2015 alone, and on their new drug, Epclusa, 
which costs around $900 per pill they could stand to make even more because of 
increased demand64.  Whatever the losses sustained in research or from lower sales of 
Harvoni and other older drugs, Gilead still stands to increase revenue by $1.8 billion this 
year.65   There is no doubt that they will make money from Epclusa nor that Epclusa is a 
better treatment and will help more people than previous generations. But how much 
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profit is necessary to stimulate innovation? A company would never invest in drugs that 
they couldn't profit from or would lose money on, and we want to invest in innovation 
and encourage companies to develop new drugs. But the cost of treating Hepatitis C 
could bankrupt our public healthcare systems.  Part of the reason why costs to our overall 
health system are going up even though Epclusa and its competitors cost less than the last 
generation of drugs is that they are effective in more patients, so demand has gone up.  
But because the drugs are priced so high, insurers are limiting who can access them, so 
one might wonder whether it is in Gilead’s or the public’s interest to maintain the high 
prices.  Setting a lower price could mean that all 2.7 million people effected by Hep C in 
the US have access to treatment, and Gilead could still make a huge profit.  Even if they 
couldn’t make more money, or even the same amount of money by making it available to 
more people, they would certainly still be making a great deal of money. While Gilead is 
certainly benefiting form the price they set, many Americans are losing out, and many 
more are becoming affected, as those with the disease pass it on to others. The incredible 
possibility created by being able to cure Hep C, is that we cannot only help those already 
effected, but can help stop the spread of the disease.  Currently a major hurdle to fighting 
Hep C, is that patients continue to practice high-risk behaviors like drug use, and pass on 
the disease to others.  But being able to cure Hep C is almost as good as a vaccine in that 
it stops patients from being able to infect others.  The truly troubling question this raises 
is whether it is in Gilead’s interest to cure everyone of Hep C, because it would mean 
they are not guaranteed a large customer base in the future.  This further raises the 
question of whether Gilead may be intentionally making their drug unaffordable to ensure 
that many people remain in need of care.   
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The problem with Hepatitis C is that its primary patient base is drug users, which 
means that before there were curative treatments that are relatively easy to follow through 
with, the amount of patients seeking treatment for their Hep C was small.  Many drug 
users were unwilling or unable to be in the hospital for long-term treatment and were 
unlikely to be aware that they carried the virus till late in the stages of cirrhosis.  With 
expansion of health insurance and healthcare, and with more ease of treatment there is a 
far greater demand for treatment, but unfortunately the prejudice against injecting drug 
users does not make them sympathetic victims of healthcare rationing.  When a child is at 
risk of death from anaphylactic shock, there is very understandable public outcry, but 
when a drug user or former drug user develops cirrhosis, they are seen to have brought 
their troubles on themselves.  Thus there is some concern that drug companies and 
insurers may not see the harm in rationing Hep C drugs, or waiting until patients get sick 
before they provide cures, because the most needy patients in Hep C cases are those who 
are seen as untrustworthy and likely to relapse.  So even if companies like Gilead are 
intentionally ensuring that many people remain sick, public outrage is not as likely if the 
victims are unsympathetic.  
This problem is further complicated by the fact that most of these high-risk 
patients will get their insurance through Medicaid and Medicare, which are in the most 
precarious financial position and have the least ability to bargain with drug companies 
over cost.  Hepatitis C is likely to cost Medicaid and Medicare 10’s of billions of dollars 
in the next five years, and the only possible means to avoiding financial disaster seems to 
be denying care, which is unconscionable, and negotiating lower prices, which is 
currently illegal.  While it is certainly true that curing more people of Hep C will reduce 
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the amount of liver transplants and hospital stays that are associated cirrhosis caused by 
Hep C, those savings won’t be seen for years. For now, the insurance industry is dealing 
with the costs of those who developed cirrhosis before a cure was available, those who 
are experiencing symptoms of cirrhosis while they wait for their disease to develop to the 
point that they qualify for the cure, and the cost of the cure.  So in reality, costs are 
getting much higher and will remain high so long as more people develop Hep C than 
there is money to cure them.   
New Hepatitis treatments align with the goal of improving health, they are 
certainly innovative, and while not without their share of serious side effects, they 
improve health outcomes for patients and can generally be regarded as both safe and 
effective. Furthermore, there were certainly high costs incurred to achieve this 
breakthrough and so there may be a justification for high prices.  One may be 
sympathetic with the argument that while prices are high they reflect future savings. Still, 
one would hope that the aim of the health industry in making technological advances is to 
improve the quality of life for patients and reduce the toll of illness on our patients and 
our wallets.  So perhaps cost savings are not as relevant as the life saving benefits of the 
drug, and justification for high costs should come from the value of the drug and the cost 
of research, not the cost savings. In my view, citing down-the-line savings for health 
insurers is a type of veiled reference to down-the-line losses for drug companies. We 
should not factor in future losses to current prices, only past losses.  The projections for 
Gilead’s revenue show an increase of over a billion dollars in profit within the first year 
of Epclusa reaching patients.  This shows that even accounting for investment in its 
research and losses on increasingly obsolete treatments, Gilead is making plenty of 
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money off their new product.  But in making these billions, Gilead is denying access to 
millions of Americans and putting our entire healthcare system in jeopardy.  By making 
their product inaccessible, Gilead is forcing patients to suffer through liver disease when 
it is no longer necessary for them to do so.  This high human cost can only be justified if 
it is necessary to pay for the development of the drug, or necessary to keep them in 
business.  This is not the case for Gilead; their high profits in the first year of selling their 
product even as huge portions of customers are excluded, show that there is room in their 
bottom line to negotiate lower prices.  With 2.7 million possible customers in the US 
alone, there is a huge margin for profit, and it is not necessary to set such high prices.   
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Chapter 3: Case Study On the Cost of Treatment of Multiple Sclerosis 
 Multiple Sclerosis, or MS, is a relatively rare and potentially debilitating disease 
of the central nervous system.  MS is generally developed by patients between the ages of 
20 and 50 with about 200,000 patients developing the disease per year in the US.  While 
the exact cause is unknown, it is likely caused by a combination of genetic and 
environmental risk factors.  In cases of Multiple Sclerosis, the patients’ immune system 
begins to attack the protective coating around nerve fibers, preventing the patient’s brain 
and spinal cord from engaging in proper communication with the rest of the body.  
Multiple Sclerosis is a progressive disease, and the deterioration of nerve coating can 
spread over time and can also become permanent.  The symptoms of MS are wide 
ranging from numbness or weakness in one or more limbs to vision problems to tingling 
and pain in any part of the body to tremors and loss of motor control66.   
 Cases of MS fall into a couple different categories, from relapsing-remitting to 
primary and secondary-progressive MS.  Most people with Multiple Sclerosis have 
relapsing-remitting disease courses in which they experience a-symptomatic periods 
broken up by relapses that may last days or weeks but which lift partially or completely; 
periods of remission may last months or even years.  However, 60-70% of people with 
relapsing-remitting MS experience a steady progression of their symptoms into 
secondary-progressive MS.  In these cases patients have an increase in the severity or 
frequency of their symptoms, and may or may not experience as many or as lengthy 
periods of remission.  The final and most rare category of MS is primary-progressive; in 
these cases patients experience a steady progression of symptoms from the onset of their 
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illness, while this progression may be very slow these patients experience no relapses or 
periods of remission67.   
 While there is still no cure for Multiple Sclerosis, there are two main avenues of 
treatment. One means of treatment is to assist in the recovery of patients after MS 
relapses or acute symptoms.  To treat acute attacks of MS, patients might use steroids to 
reduce nerve inflammation or might receive blood plasma exchanges if they have not 
responded to steroids.  Patients may attempt to relieve and manage symptoms by using 
muscle relaxants to alleviate muscle pain and spasms, or may use physical therapy and/or 
mobility aids to learn to manage their symptoms and continue on with their lives and jobs 
while fighting MS.  The other avenue, is to attempt to slow the progression of the disease 
and prevent relapses; this form of treatment is expensive and ongoing and will be the 
focus of this chapter.  There are many treatments available to modify disease progression, 
but many of them come with serious side effects and may lose their efficacy requiring 
regular evaluation and treatment changes.  Disease Modifying Treatments or DMTs were 
first introduced in 1993 and at first there were very few options, but now there are about 
ten main DMTs prescribed to MS patients68. It should be noted that there is some debate 
in the scientific community concerning the efficacy of DMTs for MS69.  I will address the 
need for more studies on the comparative efficacy of the different treatments, but I will 
be giving both companies and patients the benefit of the doubt and will work with the 
assumption that these drugs provide value to patients.   
The first class of these drugs are beta interferons, which are the most widely 
prescribed and are very effective in reducing relapses, but they carry side effects of flu 
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symptoms, require injections which may cause negative reactions, can do irreversible 
liver damage, and can lose their efficacy after prolonged periods of use.  Other first line 
medications include: 1)  Copaxone, which may stop the patient’s immune system from 
attacking the nerve coating but causes injection site reactions, 2) Tecfidera, which is 
taken orally but has digestive and immune side effects, and 3) Gilenva, another oral 
medication which reduces relapses but also slows the heart rate and causes headaches, 
high blood pressure and blurred vision.  Aubagio is another oral medication that reduces 
relapse rate, but also causes liver damage, hair loss, and can be harmful to a developing 
fetus.  Tysabri stops immune cells from reaching the spinal cord and brain, but is 
generally used as a second line defense after other medications have failed or as a first 
line in very severe cases, because blocking immune cells from the spinal cord and brain 
can put patients at a high risk of infection.  Lemtrada is another aggressive but risky drug, 
it can limit potential nerve damage caused by immune cells, but it can also inhibit the 
body’s ability to fight infection, and requires several days of hospitalization while the 
drug is administered.  Finally, Mitoxantrone is another immunosuppressant that is used in 
a very limited capacity to treat the most severe and advanced cases of MS, this drug can 
damage a patients heart and may contribute to the development of some blood cancers70.   
In the last 20 years there has been vast improvement in the number of disease-
modifying therapies available for MS, from one beta-interferon treatment in 1993 to 10 
different treatments today.  While this has provided more choice to doctors and patients, 
and has given them the ability to find the treatment that works best for each patient, there 
is still no cure for MS nor is there a drug that consistently or completely stops relapses.  
Furthermore the side effects of these drugs run the gamut from irritating to risky to 
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potentially fatal.  While the symptoms of MS and the side effects of its treatments are 
distressing enough, another layer of anxiety is added by the extreme cost of MS disease-
modifying treatments.  There is currently no DMT with a sticker price of less than 
$50,000 per year, and this is not a one-time cost, patients wishing to limit their relapses 
or manage their disease progression need to remain on DMTs for their whole life71.   
Very few individuals or insurers pay the full price for these medications, but Medicare 
does, and even after negotiations and rebates, the price remains very high for insurers, 
patients, and our health care system as a whole.  And what is further distressing about the 
price of these drugs is that despite the increase in competition, prices have gone up not 
down, defying our classical economic expectations and the common fears expressed by 
the pharmaceutical industry regarding competition.  
In the last three years there have been two major reviews of the cost of Multiple 
Sclerosis treatment.  In 2013, the Journal of Medical Economics found that the costs of 
treating MS had risen from an average of $8,500 per year in 1999 to more than $50,000 
per year in 2008.  According to this study, the rising costs of DMTs accounted for most 
of this increase72.  These rising costs pose major problems for patients, doctors and 
insurers; rising costs have contributed to increases in premiums for all insured Americans 
and these rising costs and premiums have also led to more high deductible plans and high 
co-pays.  High co-pays and deductibles are particularly problematic for MS patients since 
many are unable to work because of their disease. According to Dr. LaRocca, vice 
president of healthcare delivery and policy research at the National Multiple Sclerosis 
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Society (NMSS), “Over the last few years, the prices of MS disease-modifying drugs 
have escalated faster than inflation. Most people with MS are able to cover their 
healthcare expenses, but it is challenging and has led many of them to make 
compromises, such as skipping doses or taking drug holidays.”73 Skipping doses or taking 
smaller doses than prescribed can be very dangerous, especially in MS medications that 
have both serious side effects, and serious symptoms when drugs are ineffective; drug 
holidays, where patients temporarily stop filling their prescriptions are also very 
dangerous and put patients at risk for experiencing disease progression or relapse.  These 
cost saving measures are not things that any patient should ever have to consider.   
Another study, published by the American Academy of Neurology in 2015, 
evaluated the effect that new drugs entering the market had on the price of existing drugs 
and on the average cost of DMTs.   It is a generally accepted theory of classical 
economics that as the number of products meeting a certain demand increases, then the 
competition for buyers will drive the prices of these products down.  This should be 
especially true if newer drugs are more effective or more convenient, because older drugs 
would need to price themselves lower to compete with the better drugs, or at least this is 
what classical economists teach us.  However, the results of this study showed something 
very different.  The first drugs to treat MS came on to the market priced between $8,000 
and $12,000 per year, and after 1996 new drugs entering the market had a list price about 
25-60% higher than the old medications.  This price difference is to be expected, the 
newer medications would be offering some new value, for which they would demand a 
higher price. What is surprising, however, is large increases in the costs of first-
generation drugs, but after the approval of the third beta-interferon drug (Rebif) in 2002 
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and Natalizumab in 2006, the prices of both old and new drugs began to increase 
dramatically.  The costs of MS drugs have been increasing far faster than inflation, the 
average cost of prescription drugs in general, and even faster than other medication 
within the same class (Biologics).  If the cost of the first-generation beta-interpherons had 
been increasing at the rate of inflation, they would have cost between $12,000 and 
$19,000 per year in 2013, but instead they cost $62,000 per year.  In 2015 DMTs cost 
two to three times more in the US compared to similar countries, and there are now no 
DMTs costing less than $50,000 per year (before rebates)74.   
It is not just shocking that the cost of first-generations have increased despite 
competition, but that the first-generations have raised prices at a higher annual rate than 
their competitors, and some of the early drugs actually cost more than newer ones.  The 
average increase in prescription drug prices in America between 1996 and 2010 was 
about 3%-5% annually.  During the same period, the average annual price increase of 
first generation DMTs is 21%-36%, while the newer oral medications, have increased 
prices 8%-17% annually.  Currently, the very first MS drug ever introduced, Betaseron 
(released 1993), costs $61,000 per year while Extavia (released 2009) costs $51,000 per 
year, both of these drugs are beta-interpherons with similar modes of delivery and side 
effects.  The dramatic increase in first-generation prices seems closely tied with the 
introduction of newer drugs, but not because of some increase in manufacturing costs, 
otherwise international prices would have risen too75.  This suggests that companies 
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increased their prices in response to the prices of their competitors.  This trend defies the 
rules given to us by classical economists. John Tozzi has an interesting analogy for the 
problem with these MS drug-pricing schemes. He compares these drugs to iPhones and 
asks us to imagine if Apple sold its oldest iPhone alongside each generation of new 
iPhone and each time it released a new phone it raised the price of the older generation to 
match the price of the new phone76.  Obviously that would make no sense, no one would 
buy the older phone and they would be forced to abandon the practice.  So why is this 
working for the manufacturers of MS drugs? 
In the 2015 Neurology study, a few different reasons for this extreme increase are 
posited.  The simplest explanation, in their view, is that the drug companies are just 
taking advantage of our flawed system, which puts no limits on the prices of 
pharmaceuticals and thus allows companies to steadily increase prices in order to 
maximize profits77.  Old companies realize that there is a willingness to pay more for 
their drugs, and because there is no ability to boycott drugs there is no public or private 
sector means of limiting the price increases.  Unfortunately the payers most affected by 
these increases are Medicare patients, and taxpayers funding Medicare. Medicare is one 
of the largest health insurance providers in the United States, but is likely the only one 
paying the full sticker price for the horrendously expensive drugs in this country.  The 
Neurology study admits that the landscape of drug pricing is very complicated and there 
are more reasons than just greed leading to high prices; complications caused by patent 
monopolies, third party pharmacy benefit managers, and lack of comparative clinical 
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studies all led to our current dysfunctional system78. However, there is also very little 
transparency in these price setting decisions and that can lead some to some very cynical 
speculations, like that these price hikes suggest collusion between drug companies.  
While price data may not be enough to prove collusion, the general market trends in the 
pharmaceutical industry suggest that companies are not competing on price.   
Pharmaceutical industry representatives dispute claims that drug inflation has 
been greater than medical inflation overall.  However in the case of MS this seems to be 
false, as the costs have risen by over 20% annually for first generation drugs compared to 
the 3%-5% increase for pharmaceuticals overall79.  Another claim is that most of the 
price increases on innovative drugs are offset by price reductions in other areas as 
generics hit the market, but one could argue that drug companies have been working hard 
to prevent generics from accomplishing this balance by preventing them from reaching 
the market. They also argue that looking at the list price is not a fair measure, because so 
many of the insurers receive rebates or negotiate lower prices, and patients often receive 
help from drug companies in managing co-pays when they are prohibitive.  However, 
while this is true for private insurers, Medicaid and the VA, it is not true for Medicare 
and so both Medicare beneficiaries and taxpayers are paying the full list price for MS 
drugs.  Furthermore, waiting for and depending upon financial assistance from drug 
companies is a vary precarious position to be in as a patient and it seems like it would be 
much simpler if the drug companies would only charge a fair price for their products.   
Dr Kenneth Kaitin, Professor of Medicine at Tufts University has an interesting 
take on pharmaceutical pricing that is both skeptical of and sympathetic to drug 
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companies.  He has a healthy amount of suspicion about the pricing decisions made by 
drug companies, because he has never seen any description of their pricing process and 
there is currently no requirement or incentive for them to be forthcoming about those 
decisions.  This lack of transparency allows the companies to drive the narrative about 
drug pricing, they can claim that the high costs of research, development and brining 
drugs to market all drive up prices.  Dr. Kaitin suspects that something else is at work 
though, and that is value.   
The real factor is value. If you develop a very expensive drug that 
few people are interested in, then you’re not going to price it high 
because then even fewer people will be interested in it. In that 
regard, pharmaceuticals are just like any other commodity, any 
other product…If you develop a product that doesn’t cost too 
much to manufacture, however if it’s of tremendously high value, 
it’s going to be priced very high. 
 
Dr. Kaitin is explaining here that in some ways they are limited by the laws of supply and 
demand; they cannot charge the extreme prices they do for MS drugs for products with 
very little value.   However, because unlike other products, consumers cannot choose to 
forgo purchasing a drug, and in some ways may not even be able to go to a competitor for 
a drug if that is not covered or if it will not be effective in their case.  Dr. Kaitin 
emphasized the need for drug companies to have balanced portfolios of drugs, some that 
are high earners, like DMTs, so that they can support less profitable drugs and fund 
research efforts.  While major drug companies may not be doing very innovative research 
to find cures in house, they invest heavily in smaller labs, which often go under80.   
 Despite these defenses of drug companies price setting choices, there seems to be 
something particularly disturbing about the trend in Multiple Sclerosis medication 
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pricing.  Part of the reason for this concern is the consequences it is already having for 
patients and payers, and the fact that there is nothing really stopping the prices from 
increasing indefinitely.  These price increases are already leading to serious consequences 
for patients and insurers.  The high prices have caused insurance companies to make 
decisions on their formularies based on preferential price negotiations rather than by the 
value of the drugs to patients.  Furthermore, insurance companies have a tendency to 
deny first requests by patients for expensive drugs, causing delays for patients in 
accessing care as doctors and patients comply with the multiple approval steps.  All 
together the high costs of drugs and the responses to them by insurance companies has 
added undue burdens to patients already struggling with the stress and complications of 
serious diseases.  It seems that there are four main ethical problems with the price of 
Multiple Sclerosis drugs; 1) the backwards practice of drug companies raising prices to 
match competitors, 2) the lack of any cap or end to this inflation, 3) the rebates used to 
lower prices for patients and insurance companies rather than actually lowering prices 
and 4) the problems with the bargaining power of Medicare and patients.  
 The pricing of MS medications defies all the rules we are supposed to accept 
concerning competition and prices.  This poses a very serious objection to the way our 
pharmaceutical system works and is concerning for the future of the industry.  DMT 
prices have shown that there is no invisible hand guiding drug prices and keeping them 
affordable, even in cases where there is competition.  Each increase in price or 
introduction of a new drug has just proven that the willingness to pay for MS drugs is 
high, and each increase in price for one drug has encouraged competitors to raise prices.  
This is a very problematic system, because while it is true that there is a high willingness 
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to pay for these drugs, this willingness is coming from a point of near duress for patients 
and providers.  Patients and providers are not willing to pay the high prices, they are 
forced to pay whatever price the companies decide on because the alternative is MS 
attacks, relapses and a steady progression of symptoms.   
 These price increases seem to show that companies are not setting prices based on 
increasing manufacturing costs or other variables.   Even if companies are using their 
blockbuster or strong revenue producing drugs to pay for research ventures, it does not 
follow that these prices are reasonable.  It is in the interest of our medical system and of 
MS patients themselves for more research to go into finding better therapies and 
hopefully cures for MS and other diseases, but ever increasing costs of drugs puts a 
tremendous burden on patients and on our healthcare system.  If premiums continue to 
increase, then there won’t be enough people able to afford health insurance and support 
the system.   While MS drugs are not the only culprits in skyrocketing healthcare costs, 
their strange anti-competitive pricing is indicative of the problems associated with 
unregulated pricing, and what is even more troubling about the lack of regulation is that 
there is no end in sight to these price increases.   
 There is nothing legally stopping drug manufacturers from continually increasing 
their prices, and it is very difficult for patients, doctors and insurers to have any impact 
on prices without sacrificing patient outcomes.  Due to the lack of regulation on the drug 
industry’s price setting, unless there is some evidence of collusion among the 
manufacturers, there is really no way to stop them from continually raising prices, and so 
far there is no evidence of collusion except the strange price trends.  Without this there is 
currently no real regulatory authority to restrict these price increases.  Furthermore, as 
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mentioned before, patients and for the most part insurers have no collective means of 
demanding lower prices.  While insurers (besides Medicare) can bargain for lower prices 
or demand rebates for drugs, it is very difficult to negotiate lower prices without 
sacrificing patient outcomes.  An insurer is unlikely to be able to negotiate lower prices 
on all the MS drugs on the market because most likely negotiations involve some sort of 
price preferential, where the insurer agrees to give preference to one brand over another 
on their formulary.  This is a sacrifice of patient outcomes because patients all respond 
differently to different drugs and the insurer preference drugs may not be the most 
effective for every patient.   
 A further problem with the way prices are set is the use of rebates, which must be 
negotiated by insurers and thus excludes Medicare.  Medicare, and thus the taxpayer, 
pays a higher rate for drugs than any other payer.  By setting high prices but allowing 
negotiation the drug companies are essentially discriminating against Medicare.  While it 
is true that it is Congress that made this rule for Medicare, and pharmaceutical companies 
are just exploiting it, the fact is that the pharmaceutical companies lobbied Congress 
heavily to ensure that Medicare was denied bargaining power.  Thus the industry has 
made a loop-hole for itself that allows them a large customer base (the largest of all the 
public and private insurers) that is forced to pay whatever price they set.  This creates a 
gigantic burden for our public health care systems which are on the verge of bankruptcy 
and are shifting more and more burden on patients to pay for care.   
 Which brings us to the last problem: the unheard voice of the patient in price 
setting.  There has been much public outcry about the cost of drugs in this country, and 
while this public image crisis has led to changes in some products, most drugs remain 
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high priced and companies continue to point to rebates, or payment plans, or coupons that 
reduce co-pays, and the systemic problem remains.  The sad fact is that while patients 
and doctors can point to unfair prices and attempt to raise public awareness, they have no 
bargaining power themselves.  Doctors and patients can educate themselves on prices and 
search for low cost alternatives, but in cases like MS where no alternative exists patients 
are forced to pay up.  The healthcare system is unique because there is no option to walk 
away from the negotiating table and no boycott option.  Manufacturers and regulators 
must come to some consensus on what a fair price is, and how much a company can over 
charge in the name of investment and research.   
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Chapter 4: Policies to reduce drug prices 
The previous chapters have reviewed case studies in an attempt to understand 
whether the prices we pay for drugs are justified.  In general it seems that prices are 
unjustifiably high, but there is some opacity in the pharmaceutical industry that makes it 
difficult to fully understand whether prices are justified.  This opacity comes with its own 
ethical problems; by withholding information pharmaceutical companies are violating 
their responsibility to create fair access.  Patients and buyers have the right to information 
about the products they are buying, including information about how prices are set.  
Thus, even if we cannot determine whether all high prices are unjustified, it is clear that 
the pharmaceutical industry is not living up to its ethical obligations.  Furthermore, 
whether or not prices are unjustifiably expensive the fact remains that pharmaceuticals 
are unaffordable for many Americans; thus the American health system is not living up to 
its obligation to provide equitable access to drugs.  There is plenty of blame to be shared 
for inequitable access; many pharmaceutical companies are taking advantage of 
loopholes and other problems with our health policies, but the blame for allowing 
companies to do so is shared among the entire American population and government.  
Without the unregulated system that exists in America pharmaceutical companies would 
not be able to set high prices.  Pharmaceutical companies are in the business of making 
profit, and it is the job o the government to protect patients and consumers from unethical 
practices.  
Thus the responsibility for bringing down costs rests with the government.  There 
are several policy actions that could change the landscape of prescription drug pricing.  
These actions fall roughly into three categories: 1) enforcement of current regulations, 2) 
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creation of new legislation, or 3) amending old legislation. These proposals include 
policy recommendations as well as descriptions of some initiatives that have already been 
taken or attempted.  While they vary in their feasibility and difficulty, none of the 
recommendations listed would require an extreme overhaul of our system, but rather 
would be changes in the government regulation of pharmaceuticals and changes in the 
practices of non-government stakeholders.  I will begin with an overview of the steps that 
could be taken and conclude with some progress that has already been made.  
 
Possible actions: 
  There are several different policy avenues open to the federal government from 
stricter enforcement of current policy to the repeal of ineffective legislation to the 
passage of new legislation.  While it should be noted that the latter two would require a 
lot of political will, especially considering the recent track record of Congress in passing 
new legislation, the current debate over the future of American Healthcare could provide 
a forum for re-opening discussion of pharmaceutical regulation.  A current hurdle for 
many of these proposals will be President Trump’s Executive Order mandating that 
federal agencies repeal two regulations for every regulation they add81.  While this 
mandate does not stand in the way of more strictly enforcing the regulations currently in 
place it impedes the ability of agencies to add new regulation without going through 
Congress.  Furthermore, the Trump Administration has made many statements regarding 
the high cost of drugs and the need to address the rising prices but those statements have 
generally argued for reducing costs by deregulating the industry.  While some of the 
                                                        
81 "Presidential Executive Order on Enforcing the Regulatory Reform Agenda." The White House. 
February 24, 2017. Accessed March 04, 2017. https://www.whitehouse.gov/the-press-
office/2017/02/24/presidential-executive-order-enforcing-regulatory-reform-agenda.  
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policies recommended include the repeal of certain laws or parts of laws, these proposals 
are to remove restrictions on government interference, not to remove regulations on the 
pharmaceutical industry.   
 
 1. The existing laws and regulations that could be enforced include returning to 
the original interpretation of patent law, use of antitrust law to regulate prices, and 
tightening of FDA control over pharmaceutical advertising.  In recent years the FDA and 
many courts have weakened the restrictions on what can be patented and how patent 
challenges can be litigated82.   
 a. Patent law was written to ensure that only novel, useful and non-obvious drugs 
could receive patents and market exclusivity.  But the patent office has allowed for 
several means by which these requirements can be dodged.  Patents are issued to drug 
companies for features of drugs rather than the specific formula of the drug. This means 
that when one patent expires, the company can apply for a patent for a different feature of 
the same drug, thus obtaining a patent and 20 years of market exclusivity for absolutely 
no innovation.  This creates a problem for competition because when a feature rather than 
formula is patented then it is harder to discern whether competitors entering the market 
are truly novel, because there is no direct formula comparison to determine patent 
infringement.  Furthermore, allowing companies to get new patents for new uses of an 
old drug rather than a truly new treatment is that it both limits the entry of generics for 
both the new and old uses of the drug and limits the incentives for companies to invest in 
research for truly new drugs.  In order for a drug to receive patent protection and market 
                                                        
82 Angell, Marcia. The truth about the drug companies: how they deceive us and what to do about 
it. Melbourne: Scribe, 2006. p.424-425 
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exclusivity the drug should be new, and it should accomplish something new; it should 
not just be better than a placebo but better than the existing treatments.  To require true 
novelty and improved utility in order to receive FDA approval would require new 
regulation or law, but to require it for patent protection would simply require a changed 
interpretation of existing regulations and would have a profound effect.  Finally, the 
Patent office should remove the incentives that pay patent officers bonuses based on the 
number of cases they review.  This practice leads to more patent approvals and a more 
rushed process, because approving a patent actually takes less time than denying one83.   
 b. Antitrust law is another route of existing law that could serve to curtail the 
rising costs of drugs.  The practices of both generic and brand companies are in many 
ways very anti-competitive, and the point of antitrust law is to ensure that unlawful 
monopolies do not crop up.  This could be pointed towards Big Pharma by limiting the 
amount of mergers and buy-outs in the pharmaceutical industry and ruling against other 
anti-competitive practices, like evergreening (constantly applying for new patents on old 
drugs) and pay-for-delay (essentially bribing generic companies to delay the entry of 
competition).   
 c. Finally, the FDA already has the ability to regulate pharmaceutical 
advertising, but they currently use this power very sparingly.  The FDA currently 
regulates advertising only to make sure that companies describe the risks and side effects 
of medications and do not make overtly false claims about the benefits.  They could 
however, take more serious steps to curtail the advertising efforts of pharmaceutical 
companies.  Limiting the advertising could mean requiring that pharmaceutical 
companies state the comparative benefit that their drugs provide, or the price, or other 
                                                        
83 Ibid. pp. 427, 439 
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pertinent information.  Or the regulation could be limiting the kinds of claims that the 
pharmaceutical company can make, today many companies make statements in ads about 
the possible unintended positive effects of the drug such as weight loss or “increased 
energy” which have limited basis in research.  By using the regulating power already 
given to the FDA, we could limit the amount of misleading claims that drug companies 
make, and could possibly curb the demand for high priced drugs.  If the ads stop falsely 
driving up demand, companies might abandon them, which could pull down costs84.   
 
 2. In addition to enforcing the laws and regulations already in effect, new policies 
could be enacted to limit the rise of drug prices.  Changes could include the repeal or 
amendment of some existing laws and the creation of new laws and regulations.   
 a. Laws that should be repealed or amended are the Medicare Prescription 
Drug Benefit Reform of 2003 (Medicare Part D) and the Hatch-Waxman Act.  Both of 
these laws create loopholes for the pharmaceutical industry: limiting the power of the 
government and private actors to resist price increases.  Medicare Part D prohibits the 
director of Medicare and Medicaid Services from bargaining to lower prices for Medicare 
beneficiaries85.  This is a giant loophole that accomplishes nothing except increasing 
pharmaceutical profits at the expense of taxpayers and Medicare beneficiaries.  Medicare 
Part D also includes a provision that bans the re-importation of drugs from Canada unless 
the Director of Health and Human Services gives explicit permission.  This provision was 
included with the explanation that safety standards could not be ensured if drugs were re-
imported through Canada.  While there is virtually no evidence that drugs imported from 
                                                        
84 Ibid. pp. 448 
85 Ibid. pp. 453 
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Canada are more dangerous than drugs manufactured and directly sold in the US (and in 
fact there is some evidence that Canadian imports are safer), no Director of HHS has used 
their power to allow the importation of drugs from Canada.  It should be noted here that 
importing drugs is not a long term solution to rising drug costs, but it is an important tool 
at our disposal to be used when prices on certain drugs becomes too high.   
 The Hatch-Waxman Act should also be repealed or amended to remove the 
loopholes that exist for companies in the patent application and litigation processes86.  
This is the law that allows old drugs to be re-patented for uses outside of the original 
patent, which contributes to the practice of “evergreening,” increases costs and limits 
innovation by making old drugs more profitable than new ones.  This act has a further 
problem in its regulation of patent litigation; under this law, whenever a patent challenge 
is raised in court, an automatic 30-month window of market exclusivity is given to the 
patented product, this serves only to limit the entry of generics and competitors which 
might drive down prices, and increase the amount of frivolous law suits brought to 
lengthen market exclusivity.  Repealing or amending Hatch-Waxman would bring down 
drugs costs by allowing for more entry of generic drugs.   
 b. In addition to the amendment of old legislation, new laws and regulations 
could be created to bring down drug prices, there are possible steps to be taken at 
virtually every stage of the pharmaceutical industry: from research to clinical trials to 
patenting to regulating pricing and requiring transparency.  To start, there are important 
changes that can be made to the way clinical trials of drugs are conducted. Currently, 
clinical trials only have to show that a drug has more benefit than a placebo and has 
minimal harmful side effects, but new policy should be made requiring that drugs not 
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only be tested against placebos, but against drugs already on the market for the same 
purpose87.  Along with this new policy would be several others to support it, including 
making all study results public so that companies cannot bury negative results, and a 
reorganization of the exclusivity period granted after patent and FDA approval.  A 
reorganization of the market exclusivity would mean a reduction in the amount of years 
that a company was granted exclusivity (currently the period is 20 years), but the 
exclusivity would begin after the drug finished clinical trials and received FDA approval.  
This policy change would have several positive effects, it would lesson the amount of 
time of market exclusivity, allowing for competition to begin sooner and prices to go 
down, it would reduce the rush that is placed on clinical trials since they would no longer 
eat into the exclusivity period and our knowledge of the drugs on market and our 
consumer power would be increased since we would have more information about the 
relative effectiveness of new drugs.   
 In order to accomplish these changes there would need to be some changes made 
to the operations of the FDA.  This is one of the more difficult policies to enact as it 
would require more government investment in the FDA and would remove a lot of the 
influence of drug companies on FDA practices.  In order to make sure that the FDA is 
serving the public by regulating drug companies and ensuring the development and 
distribution of safe and useful drugs, we need to get the FDA out of the pockets of Big 
Pharma.  Currently the FDA is essentially paid by the pharmaceutical industry to review 
their drugs as they are required to pay “user fees” to the FDA when they submit a drug 
for approval. While this policy was enacted to ease some of the financial burden from the 
federal government, its result has been that the FDA is now incentivized to review and 
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approve new drugs88. Along with the reform of clinical trials, this would hopefully reduce 
the amount of frivolous trials and refocus the industry on putting forward truly innovative 
drugs, and with more funding from the government, the FDA could serve its purposes of 
protecting people from harmful drugs and making sure that new drugs are useful and 
worth the price we pay.  In order to accomplish any of these FDA reforms we would first 
need to remove those with ties to the pharmaceutical industry from the FDA advisory 
boards, as these boards are currently populated with people who have conflicts of 
interests and incentives to keep the FDA working for companies rather than people.   
 Once there is more adequate research into the comparative effectiveness of 
various drugs and once Medicare can join the rest of the healthcare payers in advocating 
lower prices, an “indication specific” model for pricing can be used.  An indication 
specific pricing model uses the comparative effectiveness of drugs to establish their 
value89.  Currently, any new drug on the market is likely to cost twice as much as an older 
version whether it provides more patient benefit or not.  While some hospitals, doctors 
and insurers have taken the initiative to refuse to purchase and prescribe marked up drugs 
with no added benefit, there is currently no national system for comparing the cost 
effectiveness of drugs within the same class.  This needs to be changed if all the various 
payers and stakeholders are going to make informed decisions about which drugs to buy 
and how much to pay.   
 The final step in creating new policy is accountability.  Drug companies need to 
be held accountable for their practices and the effects of their drugs.  This starts with an 
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89 Pearson, Steven, MD, MSc FRCP, Bill Dreitlein, PharmD, BCPS, and Chris Henshall, PhD. 
"Indication-specific pricing of pharmaceuticals in the United States Health Care System" Institute for 
Clinical and Economic Review . March 2016. Accessed October 2016. 
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opening of the books, drug companies need to be required to break down their expenses 
more thoroughly and be more honest about their practices90. If some of the Research and 
Development budget goes into market research rather than drug research, we have the 
right to know and if “outreach and administration” includes lobbying and marketing 
drugs to doctors and medical students, than we should have the right not to pay for those 
expenses.  Furthermore, companies should have outcome accountability, if a drug doesn't 
work for a patient then that patient should not have to pay for the treatment they received.  
This is a policy that has been successfully implemented in countries like Denmark, and 
has reduced expenses and drug dependency in the healthcare industry, since companies 
no longer push drugs on those who are unlikely to be helped by them.    
 
Policy already initiated:  
I have enumerated many ways by which we might bring pharmaceutical prices 
down, or at least stop them from rising quite so rapidly.  Currently, two bills await 
hearings in the Senate Finance Committee, both aimed at lowering the costs Americans 
face in purchasing prescription drugs.  These two bills address some of the policy 
proposals I outlined above, but they are both rather modest in their scope.  
The first of these bills was introduced by Bernie Sanders, the Independent Senator 
from Vermont and 2016 Democratic Presidential Candidate, and co-sponsored by 
Representative Elijah Cummings, a Democrat from Maryland. This bill, “The 
Prescription Drug Affordability Act of 2015” outlines several different strategies for 
tackling the problem of rising drug prices including Medicare Part D negotiations, re-
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importation of prescriptions from Canada, Medicare and Medicaid rebates, prohibiting 
“pay for delay,” harsher penalties for fraud committed by pharmaceutical companies and 
requirements for more transparency in pharmaceutical costs and prices.  Many of these 
policy proposals have already come up in this investigation of drug prices, particularly 
Medicare negotiation and prohibiting “pay for delay.91”  
The other piece of legislation, also stalled in committee, is a bi-partisan proposal 
from Senator Wyden and Senator Grassley called “Reducing Existing Costs Associated 
With Pharmaceuticals For Seniors Act of 2016.”  While this bill is mostly targeting the 
costs of drugs for seniors, it’s policies, particularly the call for transparency, could have 
ripple effects in the broader landscape of drug prices.  This bill would also increase the 
rebates given to Medicare by drug companies, and the rebates given to seniors by 
Medicare.  Requiring greater rebates for Medicare (similar to those given to Medicaid) 
would limit the costs to the federal government in providing prescription drug benefits, 
and allow more money to give to seniors who still struggle to pay the co-pays for their 
prescription drugs.  This bill would also give the Director of HHS the ability to negotiate 
directly with drug companies to bring down costs.  This would be accomplished by 
leveraging the power the Federal Government has as this single largest contributor to 
pharmaceutical research92.   
While these policies are not sweeping and do not comprehensively solve the 
issues of the pharmaceutical industry, they all would make a difference in bring down 
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costs or keeping them from going up.  The bottom line is that something needs to be 
done, because the current cost landscape is unsustainable.  Many of these policies would 
be very difficult to enact because the pharmaceutical industry has so much power in 
Washington DC and there is very little consensus among representatives about what 
causes high prices and what the solutions should be, thus the two bills mentioned have 
each been waiting for a vote in the Senate Finance Committee for over a year.   
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Chapter 5: Policy Recommendations By Case Study 
 I have reviewed some strategies for combating high drug prices, but now I will 
put them into context by applying these policy changes to the EpiPen, Hepatitis C and 
Multiple Sclerosis case studies.  While none of the strategies I outlined would likely raise 
prices, they would likely have different effects on different classes of drugs.  While there 
were certainly similarities between each of the cases, there were also slight differences in 
the causes of the high prices.  EpiPen, more than the other cases, owed much of its price 
hikes to the costs of marketing and lobbying and to the secrecy surrounding the spending 
of drug companies.  Therefore the policies most effective in addressing the costs of 
EpiPen, would be those curtailing the spending of companies on marketing and lobbying 
and those requiring that spending breakdowns be made public.  However, with Hepatitis 
C Treatments, the biggest problems are the inability of all insurers to negotiate.  Finally, 
the largest problems with Multiple Sclerosis treatments are the lack of comparative 
effectiveness information, and the resulting ability of companies to increase their prices 
to match the cost of new drugs, even if there are no improvements to the drugs.  While I 
have highlighted the current problems of each drug and the corresponding policy 
solutions, this is not to suggest that other policies would not work in the present or future 
to bring down the costs of those drugs. For example, all of these drugs would or could 
benefit from amendments to patent and FDA policies as well as more negotiating power.   
 As mentioned, EpiPen would benefit from policies that focus on marketing 
spending and transparency.  It is very difficult to know exactly how much it costs Mylan 
to produce EpiPen, how much they spent on minor changes to the device and how much 
was spent on marketing and “education”.  However, while we do not know the exact 
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breakdown of Mylan’s EpiPen costs, we do know that there have been increases in 
advertising and lobbying efforts of Mylan.  This information, or lack there of, presents 
some key problems and policy solutions.  Until recently brand name EpiPen was 
practically the only option for epinephrine auto-injectors, and so the public was forced to 
pay whatever price Mylan set.  Mylan has insisted that the $600 price was a fair one, but 
has not backed up this claim by revealing any information about their costs. Without this 
information, we cannot hold drug companies accountable for setting fair prices. 
Furthermore, there is still the suspicion that most of the expenses leading to high prices 
are advertising and lobbying costs, which creates several problems of its own. Companies 
should not expect that the government, which buys its products, pay for the efforts to 
lobby them and the American people.  I see the process for addressing this as falling into 
3 steps, first, drug companies like Mylan need to open up their books to the public so that 
we can make informed decisions about our purchases and better understand what they are 
paying for.  Then, once this information is public, either the government should take 
action to set caps on the amount of money that can be spent on lobbying and ads or use 
the FDA to limit the amount of advertising done without setting price caps.  If the 
government chose not to take action after information was made public, then private 
individuals or organizations could take action to use their purchasing power to demand 
that drug companies prioritize innovation over marketing and bring down costs.  In the 
case of Mylan, after the public outcry over high prices, both Mylan and CVS released 
generic auto-injectors.  While this was not initiated by any government policy change, it 
does show how public interest into prices can effect the actions of companies.  Thus 
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releasing the information about the spending of drug companies has the potential to 
create public pressure for drug companies to change.  
 Unlike with EpiPen, the biggest challenge facing the price of the Hepatitis C is 
the lack of bargaining power given to the state insurers.  There is such a demand for the 
newer curative treatments for Hepatitis C, that these medications could cost Medicare and 
Medicaid $65 billion over the next 5 years, and have the potential to bankrupt many state 
Medicaid programs.  This has led to rationing of these treatments, with patients being 
forced to wait until they have sustained irreversible liver damage until they can receive 
their curative treatments.  If Medicare and Medicaid were both able to use their 
bargaining power at a national level, than they could bring down those costs, saving 
money and providing more treatments to more people.  The two Senate bills I already 
mentioned would both accomplish this goal by allowing the director of the Health and 
Human Services Department to negotiate for lower prices.  
 Finally, in the case of Multiple Sclerosis, the largest contributor to high prices is 
the lack of comparative effectiveness studies for new medications.  If each new multiple 
sclerosis drug had to prove that it was better than the existing ones in order to get a 
patent, then we may not have seen each new drug set its price above the existing ones, or 
the existing drugs raise their prices to match the new drugs.  If we knew the comparative 
effectiveness of drugs than we could have value based pricing, where drugs that provide 
more benefit can cost proportionally more, but drugs with equal or lesser value must 
reflect that value in the price.  In order to make value based pricing universal, the FDA 
and patent office would need to make comparative effectiveness studies a part of the 
process for getting approval.  This would require some significant changes to law and 
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regulation as well as more capital investment in the FDA.  Without government oversight 
of comparative effectiveness studies there is no way to make them universal, we instead 
must rely on private studies, which are subject to bias since they are often funded by drug 
companies.  There must be some sort of government intervention in creating these studies 
or we will continue to see prices rise without knowing for sure if the costs are tied to real 
patient benefits.   
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Appendix 
 
A1: Organization of Economic Co-operation and Development review of drug 
expenditure per capita in 29 developed nations.  The US is on shown on the far left, 
spending $1,026 per capita, compared the to OECD average (shown in red) of $515 per 
capita.   
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A2: The rise of prescription drug spending in the US from 2005 to 2014, with projections 
to spending in 2024.   
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A3: The OECD calculated expenditure on overall health services, public and private.     
 
A4: Cost increase of 9 MS DMTs compared with average consumer product inflation and 
the inflation of prescription drug costs specifically.   
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A5: An overview of the increases in price for nine MS disease modifying drugs.  The 
initial cost is adjusted for inflation to the comparable cost if the drug was released in 
2013, and compared to the actual cost in 2013. 
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